top-left-banner

Thursday, Aug 21st

Last update01:39:56 PM GMT

TwitterLinkedinYoutubeGoogleFeed

Banner

User1

User2c

User3

You are here: BioMedTech

BioMedTech

Valley-Cambridge personalised medicines alliance

Dr Darrin Disley, CEO of HorizonSilicon Valley translational medicines giant, Crown Bioscience, Inc. and Cambridge UK personalised medicines pioneer Horizon Discovery have forged an alliance to accelerate cures for cancer geared to sufferers’ individual genetic make-up.

Big Pharma locks into Cambridge drug advance

CEO Eddy LittlerDomainex Ltd, a Cambridge UK drug discovery company, has stirred the interest of global pharmaceutical giants with technology advances in the fields of psoriasis and Chronic Obstructive Pulmonary Disease (COPD).

Pedersen creates stem cell drug powerhouse

Professor Roger Pedersen. Image copyright – 2012 University of CambridgeA Cambridge University technology team that developed a way to generate liver cells from skin cells has formed a new company to supply stem cell products to the drug discovery and regenerative medicine sectors.

Cambridge Healthcare expands Tech City presence

Cambridge Healthcare CEO, Dawson KingCambridge Healthcare has added a second and larger office in London’s Tech City to its Cambridge and Beijing operations.

Antibodies powerhouse to raise more millions

Kymab Chairman and CEO Andy SandhamCambridge UK antibodies startup Kymab has signalled its intention to raise new multimillion pound funding as it accelerates its strategy to become a global ‘blockbuster drug’ factory.

Tristel eyes bigger profits as exports soar

Tristel infection control productBroker finnCap gave a rousing endorsement of Cambridge technology company Tristel after excellent full year results for the UK infection and contamination control specialist.

HealthTec business expands Cambridge HQ

Global Healthcare Exchange 's new HQHealthcare technology and services company, Global Healthcare Exchange (GHX), has massively expanded its European headquarters in Cambridge UK.

Abcodia seeks approval for cancer screening market panel

Dr Julie Barnes, CEO AbcodiaCambridge biomarker technology specialist Abcodia is set to ask the FDA to approve a novel cancer screening marker panel based on data being generated under one of its many collaborations.

Page 52 of 124